RGEN

Repligen Corp

147.25

Jul 17 • 03:59PM ET -1.30 (-0.88%)

147.25

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Medical Instruments & Supplies USA Mid NASD

Peers: TECH MTD BIO BRKR A WAT HALO TMO DHR IDXX

| Held by: IJH VTI VB VBK FBT VXF MDY IBB SPMD IWR

Scroll to Statements

Index	-
Market Cap	8.31B
Enterprise Value	8.21B
Income	51.40M
Sales	763.34M
Book/sh	37.33
Cash/sh	13.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2000
IPO	Apr 29, 1986

P/E	162.10
Forward P/E	57.15
PEG	2.35
P/S	10.88
P/B	3.94
P/C	10.59
P/FCF	79.51
EV/EBITDA	46.13
EV/Sales	10.75
Quick Ratio	7.78
Current Ratio	9.20
Debt/Eq	0.33
LT Debt/Eq	0.32
Option/Short	Yes / Yes

EPS (ttm)	0.91
EPS next Y	2.58
EPS next Q	0.45
EPS this Y	17.18%
EPS next Y	28.58%
EPS next 5Y	24.35%
EPS past 3/5Y	-35.60% -4.91%
Sales past 3/5Y	-2.70% 15.05%
EPS Y/Y TTM	322.84%
Sales Y/Y TTM	17.36%
EPS Q/Q	42.58%
Sales Q/Q	14.83%
Earnings	Jul 28 BMO
EPS/Sales Surpr.	24.97% 1.15%

Insider Own	5.44%
Insider Trans	-0.17%
Inst Own	118.25%
Inst Trans	7.22%
ROA	1.78%
ROE	2.51%
ROIC	1.85%
Gross Margin	47.85%
Oper. Margin	7.79%
Profit Margin	6.73%
SMA20	4.69%
SMA50	14.67%
SMA200	5.10%
Trades

Shs Outstand	56.40M
Shs Float	53.34M
Short Float	11.34%
Short Ratio	5.30
Short Interest	6.05M
52W High	175.77 -16.23%
52W Low	100.99 45.81%
Volatility	2.92% 4.32%
ATR (14)	5.62
RSI (14)	63.48
Beta	1.03
Rel Volume	0.80
Avg Volume	1.14M
Volume	912,389

Perf Week	2.09%
Perf Month	11.82%
Perf Quarter	15.86%
Perf Half Y	-9.12%
Perf YTD	-10.14%
Perf Year	18.71%
Perf 3Y	-3.20%
Perf 5Y	-26.43%
Perf 10Y	444.16%
Recom	1.36
Target Price	176.28
Prev Close	148.55
Price	147.25
Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-26	Upgrade	The Benchmark Company	Hold → Buy	$185
Jun-02-26	Resumed	Wolfe Research	Outperform	$145
May-15-26	Resumed	RBC Capital Mkts	Outperform	$160
Apr-17-26	Initiated	Rothschild & Co Redburn	Buy	$160
Oct-01-25	Initiated	HSBC Securities	Buy	$150
Sep-22-25	Upgrade	Evercore ISI	In-line → Outperform	$155
Jul-22-25	Resumed	Stephens	Overweight	$160
Jun-24-25	Initiated	Barclays	Overweight	$150
Apr-29-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$160
Mar-18-25	Initiated	Evercore ISI	In-line	$155
Feb-10-25	Initiated	TD Cowen	Buy	$200
Dec-17-24	Initiated	Canaccord Genuity	Hold	$165
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Aug-28-24	Initiated	Wells Fargo	Overweight	$180
Jun-26-24	Upgrade	Deutsche Bank	Hold → Buy	$180 → $155
Jun-18-24	Initiated	Guggenheim	Neutral
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight	$185
Jul-05-23	Resumed	JP Morgan	Overweight	$220
Mar-28-23	Initiated	The Benchmark Company	Buy	$230

Show Previous Ratings

Jul-15-26 07:30AM	Repligen to Report Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-07-26 09:36AM	SpaceX initiated, Cloudflare upgraded: Wall Street's top analyst calls (The Fly)
May-22-26 07:30AM	Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference (GlobeNewswire)
May-20-26 07:30AM	Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report (GlobeNewswire)
May-07-26 07:30AM	Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference (GlobeNewswire)
12:52PM	Loading…
May-05-26 12:52PM	Repligen Corporation Q1 2026 Earnings Call Summary (Moby) +6.26%
07:36AM	Repligen: Q1 Earnings Snapshot (Associated Press)
07:00AM	Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance (GlobeNewswire)
Apr-22-26 07:30AM	Repligen to Report First Quarter 2026 Financial Results (GlobeNewswire) -6.25%
Apr-17-26 09:36AM	Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls (The Fly)
07:30AM	Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network (GlobeNewswire)
Mar-05-26 07:30AM	Repligen Corporation to Present at Upcoming March Conferences (GlobeNewswire)
Mar-02-26 11:06PM	3 Reasons to Avoid RGEN and 1 Stock to Buy Instead (StockStory)
Feb-25-26 01:47PM	Analyst Report: Repligen Corporation (Morningstar Research)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
04:32PM	Loading…
Feb-24-26 04:32PM	Repligen Corporation Q4 2025 Earnings Call Summary (Moby)
04:02PM	Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ... (GuruFocus.com)
12:49PM	Repligen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:47AM	Repligen: Q4 Earnings Snapshot (Associated Press Finance)
07:37AM	Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations (StockStory)
07:30AM	Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-22-26 10:13PM	Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-19-26 11:43PM	2 of Wall Street's Favorite Stocks Worth Investigating and 1 We Avoid (StockStory)
Feb-10-26 07:30AM	Repligen to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-06-26 08:16AM	What Makes Repligen Corporation (RGEN) an Investment Choice? (Insider Monkey)
Feb-04-26 08:04PM	Analyst Report: Repligen Corporation (Morningstar Research)
Jan-26-26 11:01PM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:52PM	UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds (Insider Monkey)
Jan-14-26 02:15PM	Why Repligen (RGEN) Shares Are Sliding Today (StockStory)
07:30AM	Loading…
Jan-06-26 07:30AM	Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair (GlobeNewswire)
Dec-18-25 07:30AM	Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-17-25 08:35AM	Here's Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN) (Insider Monkey)
Dec-16-25 07:30AM	Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows (GlobeNewswire)
Dec-07-25 11:35PM	1 Volatile Stock to Target This Week and 2 We Turn Down (StockStory)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Nov-26-25 07:30AM	Repligen Corporation to Present at Evercore Healthcare Conference (GlobeNewswire)
Nov-21-25 07:09PM	Analyst Report: Repligen Corporation (Morningstar Research) +5.28%
06:36PM	Why Repligen (RGEN) Stock Is Trading Up Today (StockStory)
Nov-06-25 10:31PM	Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Nov-04-25 07:30AM	Repligen Corporation to Present at Upcoming November Conferences (GlobeNewswire)
12:32AM	5 Revealing Analyst Questions From Repligen's Q3 Earnings Call (StockStory)
Oct-30-25 07:45PM	Analyst Report: Repligen Corporation (Morningstar Research)
Oct-29-25 01:13PM	Analyst Report: Repligen Corporation (Morningstar Research)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:40AM	RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset (StockStory)
Oct-28-25 02:35PM	Why Repligen (RGEN) Shares Are Trading Lower Today (StockStory) -5.92%
08:45AM	Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:01AM	Repligen's (NASDAQ:RGEN) Q3 Sales Beat Estimates (StockStory)
07:40AM	Repligen: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Oct-27-25 09:22AM	Earnings To Watch: Repligen Corp (RGEN) Reports Q3 2025 Result (GuruFocus.com)
Oct-26-25 11:13PM	Repligen Earnings: What To Look For From RGEN (StockStory)
Oct-23-25 07:15PM	Analyst Report: Repligen Corporation (Morningstar Research)
10:00AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 11:40AM	ALKS vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
10:00AM	Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline (Zacks)
Oct-15-25 07:30AM	Repligen to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-09-25 07:46AM	Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? (Insider Monkey)
Oct-01-25 12:20PM	Why Is Repligen (RGEN) Stock Soaring Today (StockStory) +9.08%
Sep-30-25 04:05PM	Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know (StockStory) +7.72%
Sep-24-25 12:04AM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Sep-22-25 11:31PM	Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Sep-16-25 02:51PM	Repligen (RGEN) Stock Is Up, What You Need To Know (StockStory) +5.28%
Sep-12-25 02:26PM	Why Repligen (RGEN) Stock Is Down Today (StockStory)
Aug-22-25 03:40PM	Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know (StockStory)
07:30AM	Repligen Corporation to Present at Upcoming September Conferences (GlobeNewswire)
Aug-20-25 08:42AM	Do Options Traders Know Something About Repligen Stock We Don't? (Zacks)
Aug-12-25 12:53AM	RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty (StockStory) +8.51%
12:35AM	5 Must-Read Analyst Questions From Repligen's Q2 Earnings Call (StockStory)
Aug-07-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-31-25 07:30AM	Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization (GlobeNewswire)
Jul-29-25 11:52PM	Analyst Report: Repligen Corporation (Morningstar Research)
02:26PM	Why Repligen (RGEN) Stock Is Up Today (StockStory)
08:45AM	Repligen (RGEN) Lags Q2 Earnings Estimates (Zacks)
08:09AM	Repligen's (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic (StockStory)
07:41AM	Repligen: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Jul-28-25 09:22AM	Repligen Corp (RGEN) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-27-25 11:06PM	Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-22-25 09:40AM	Netflix downgraded, Intel initiated: Wall Street's top analyst calls (The Fly)
Jul-21-25 09:45AM	Here's Why Repligen (RGEN) is a Strong Growth Stock (Zacks)
Jul-18-25 03:11PM	Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know (StockStory) -6.28%
12:03AM	3 Reasons RGEN is Risky and 1 Stock to Buy Instead (StockStory)
Jul-17-25 07:30AM	Repligen to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 02:18PM	5 Insightful Analyst Questions From Repligen's Q1 Earnings Call (StockStory)
Jun-16-25 08:00AM	908 Devices Appoints Christopher D. Brown to its Board of Directors (Business Wire)
Jun-04-25 11:36PM	Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Jun-03-25 11:32PM	Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers (StockStory)
Jun-02-25 01:36PM	Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? (Zacks)
May-29-25 11:30AM	Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? (Zacks)
May-27-25 07:30AM	Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report (GlobeNewswire)
May-22-25 07:30AM	Repligen Corporation to Present at William Blair Growth Conference (GlobeNewswire)
May-09-25 12:36AM	1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar (StockStory)
May-07-25 07:30AM	Repligen Corporation to Present at Upcoming May Investor Conferences (GlobeNewswire)
May-02-25 11:40AM	QGEN or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
08:18AM	Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare (Insider Monkey)
May-01-25 12:11PM	Jim Cramer on Repligen Corporation (RGEN): 'I'm Not Quite Ready to Stick My Neck Out on This One' (Insider Monkey)
Apr-30-25 04:19PM	RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty (StockStory)
10:55AM	Analyst Report: Repligen Corporation (Morningstar Research)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

PresidentMr. Olivier Loeillot

CFO & Chief Compliance OfficerMr. Jason K. Garland

Chief Operating OfficerMr. James R. Bylund

AdvisorMr. Anthony J. Hunt

Senior Vice President of Research & DevelopmentMr. Ralf Kuriyel

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garland Jason K	CFO	Jul 16 '26	Sale	150.00	530	79,500	18,829	Jul 17 04:40 PM
Garland Jason K	Officer	Jul 16 '26	Proposed Sale	150.00	530	79,500		Jul 16 01:45 PM
Garland Jason K	CFO	Jun 25 '26	Sale	145.00	733	106,285	19,359	Jun 26 04:05 PM
Garland Jason K	Officer	Jun 25 '26	Proposed Sale	145.00	733	106,285		Jun 25 01:55 PM
MUIR GLENN P	Director	May 07 '26	Option Exercise	38.76	2,434	94,342	39,056	May 08 02:48 PM
Loeillot Olivier	Chief Executive Officer	Apr 21 '26	Sale	140.00	3,832	536,480	54,246	Apr 22 01:26 PM
Loeillot Olivier	Officer	Apr 21 '26	Proposed Sale	140.00	3,832	536,480		Apr 21 12:44 PM
DAWES KAREN A	Director	Dec 17 '25	Sale	161.00	275	44,275	91,821	Dec 18 04:30 PM
MUIR GLENN P	Director	Dec 16 '25	Option Exercise	26.12	3,366	87,920	36,622	Dec 17 04:30 PM
DAWES KAREN A	Director	Dec 17 '25	Proposed Sale	161.00	275	44,275		Dec 17 04:28 PM
Loeillot Olivier	Chief Executive Officer	Nov 25 '25	Sale	170.00	7,041	1,196,970	35,898	Nov 26 04:30 PM
Loeillot Olivier	Officer	Nov 25 '25	Proposed Sale	170.00	7,041	1,196,970		Nov 25 12:06 PM
Bylund James	Chief Operating Officer	Nov 18 '25	Sale	151.21	2,191	331,301	21,520	Nov 19 04:30 PM
Bylund James	Officer	Nov 18 '25	Proposed Sale	151.21	2,191	331,304		Nov 18 04:10 PM
Hunt Anthony	Director	Nov 13 '25	Option Exercise	33.87	2,952	99,984	83,695	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Sale	154.61	20,000	3,092,278	80,743	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Option Exercise	33.87	25,000	846,750	125,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Sale	156.88	25,000	3,921,940	100,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Proposed Sale	154.62	20,000	3,092,327		Nov 13 04:11 PM
Hunt Anthony	Director	Nov 12 '25	Proposed Sale	156.88	25,000	3,921,981		Nov 12 04:37 PM
Hunt Anthony	Director	Sep 10 '25	Option Exercise	33.87	20,000	677,400	129,854	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Sale	120.52	29,111	3,508,389	100,743	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Proposed Sale	120.52	29,111	3,508,378		Sep 10 04:22 PM
Madaus Martin D	Director	Aug 08 '25	Buy	112.13	1,800	201,830	1,800	Aug 12 12:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGEN

Repligen Corp

Upgrade your Finviz experience